---
schema_version: "secwatch.filing_event.v1"
accession: "0001860742-24-000016"
form_type: "8-K"
ticker: "BLCO"
cik: "0001860742"
company_name: "Bausch & Lomb Corp"
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:32:51.473461+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bausch + Lomb Q3 revenue $1.196B (+19% YoY); raises FY2024 revenue guidance

## Summary
- GAAP net income $4M vs net loss of $84M YoY; adjusted EPS $0.13 ($0.17 ex-IPR&D).
- Adjusted EBITDA $212M ($227M ex-IPR&D) vs $187M YoY, driven by broad-based sales growth.
- Pharmaceuticals revenue surged 76% to $306M on XIIDRA acquisition and MIEBO launch.
- FY2024 revenue guidance raised to $4.725-4.825B (prior $4.70-4.80B); adjusted EBITDA outlook unchanged.
- Cash flow from operations $154M, up from $48M YoY, aided by gross profit and working capital.

## SEC filing metadata
- accession: 0001860742-24-000016
- form_type: 8-K
- ticker: BLCO
- cik: 0001860742
- company_name: Bausch & Lomb Corp
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860742/000186074224000016/0001860742-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860742/000186074224000016/blco-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001860742-24-000016
- JSON: https://secwatch.observer/filing/0001860742-24-000016.json
- Plain text: https://secwatch.observer/filing/0001860742-24-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.